Infliximab

Higher visceral adipose tissue correlated with lower rates of inflammatory bowel disease remission among patients dosed with infliximab, vedolizumab or ustekinumab, according to Andres Yarur, MD, Medical College of Wisconsin.

Patients with inflammatory bowel disease who switched from one infliximab biosimilar to another had no significant change in disease activity, according to research published in Alimentary Pharmacology and Therapeutics.

Methotrexate increases the probability of remission with adalimumab or infliximab by 50% in patients with psoriatic arthritis, versus TNF-inhibitor monotherapy, according to data published in the Annals of the Rheumatic Diseases.

Biologic infusions administered at home are associated with a 25% increased risk for hospital admission the same or next day, and a 28% higher risk for permanent discontinuation, compared with facility-given infusions, according to data.

On May 11, Icelandic-based drug developer Alvotech filed a lawsuit against AbbVie seeking to undo what it alleges is a “minefield” of “invalid” patents surrounding what is arguably the pharma giant’s most prized possession: Humira.

Researchers identified novel candidate biomarkers for infliximab response after unsupervised plasma proteomic analysis in pediatric patients with Crohn’s disease, according to a presentation at Digestive Disease Week.

Patients who are immunosuppressed will “likely” need regular COVID-19 vaccine boosters in the future, according to Jeffrey R. Curtis, MD, MS, MPH, chair of the American College of Rheumatology COVID-19 Vaccine Clinical Guidance Task Force.

Patients who received Remicade for inflammatory bowel disease had weakened anti-COVID-19 antibody responses following a single vaccination dose, according to research published in Gut.

Discontinued long-term use of infliximab correlated with lower rates of maintained remission in patients with ulcerative colitis, according to research published in The Lancet Gastroenterology and Hepatology.

Anti-COVID-19 antibody responses are attenuated in patients who receive infliximab for inflammatory bowel disease, according to a speaker at the 2021 Interdisciplinary Autoimmune Summit.